Last updated: February 15, 2026
What is NDC 00555-0635?
NDC 00555-0635 is the National Drug Code for a specific pharmaceutical product. It is identified as Humira (adalimumab) prefilled syringe used in autoimmune conditions, including rheumatoid arthritis, Crohn's disease, and psoriasis.
Current Market Landscape
Humira is one of the highest-revenue drugs globally, with annual sales exceeding $20 billion in recent years, making it a dominant player in biologic therapies.
Key Competitors
- Enbrel (etanercept)
- Stelara (ustekinumab)
- Remicade (infliximab)
Market Dynamics
- The US accounts for roughly 50% of annual Humira sales
- Global sales are projected to surpass $40 billion in 2023
- Post-patent expiration in the US (2023), biosimilar competition will increase, though recent legal challenges impact timing
Patent and Regulatory Status
- The original patent expired in January 2023 in the US, opening market to biosimilars
- Several biosimilars have gained FDA approval, including Amgen's Amjevita and Samsung Bioepis' Hadlima
- Geographic variation exists; Europe and other markets have earlier biosimilar entry
Market Opportunities and Risks
Opportunities:
- Growing prevalence of autoimmune diseases
- Expanded indications approved over time
- Potential for biosimilar volume share gains
Risks:
- Biosimilar adoption barriers
- Pricing pressures from competition
- Regulatory delays impacting biosimilar market entry
Pricing Trends and Projections
Current Pricing
- List price for Humira prefilled syringe in the US: approximately $2,400 per pen (as of 2023)
- Estimated wholesale acquisition cost (WAC): approximately $2,100 per syringe
- Biosimilar prices range from 15% to 25% below the originator
Post-Patent Price Trajectory
| Year |
Estimated Average Price (US, per syringe) |
Comments |
| 2023 |
$2,100 - $2,400 |
Transition period; biosimilars entering the market |
| 2024 |
$1,950 - $2,200 |
Biosimilar competition impacts originator pricing |
| 2025+ |
$1,800 - $2,050 |
Potential stabilization; biosimilar volume gain |
Note: These projections assume continued biosimilar penetration, with aggressive discounting and formulary shifts.
Pricing Factors Influencing Future Costs
- Patent litigation outcomes: Extended legal battles can delay biosimilar discounts
- Rebates and discounts: Payer negotiations can substantially lower net prices
- Market penetration: Biosimilar acceptance is incremental; adoption speed varies
- Manufacturing costs: Stable for biologics but standard for biosimilars due to scale efficiencies
Market Volume and Revenue Forecasts
Based on epidemiological data, the US autoimmune patient population exceeds 10 million, with approximately 30% treated with biologics like Humira. Globally, the biosimilar market is expected to grow at a CAGR of 13% from 2023 to 2030.
| Year |
Estimated US Revenue (Billion USD) |
Global Revenue (Billion USD) |
| 2023 |
$10.3 |
$20.8 |
| 2025 |
$8.6 |
$17.4 |
| 2030 |
$6.5 |
$13.2 |
Projections account for biosimilar uptake, price reductions, and new indications.
Key Market Entry and Pricing Strategies
Initial biosimilar prices are 15-25% below originator list prices, with further discounts through formulary negotiations. Manufacturers may implement rebate strategies to retain market share and combat price erosion.
Conclusion
Post-patent expiration, NDC 00555-0635's market will see significant biosimilar competition, leading to a decline in retail prices. The originating biologic remains dominant in volume due to physician and payer inertia. Long-term prices are projected to settle between 25-35% below current list prices, with total US revenues declining by approximately 20-30% by 2025, assuming continued biosimilar uptake.
Key Takeaways
- NDC 00555-0635 refers to Humira prefilled syringes, a blockbuster biologic with >$20 billion annual sales.
- The patent expiry has led to biosimilar entry, pressuring prices.
- US list prices are around $2,400; post-expiry, prices are projected to decline to $1,800-$2,050 per syringe.
- Biosimilar competition will reduce revenue share for the originator but may expand overall market volume.
- Pricing and adoption rates will depend on legal, regulatory, and payer dynamics.
FAQs
1. When will biosimilars fully impact the US market for NDC 00555-0635?
Biosimilar market share is expected to stabilize by 2025-2026, though legal and market factors can delay full impact.
2. How much will prices decrease with biosimilars?
Current estimates project a 15-25% reduction from current list prices, with further declines over time.
3. Will the originator maintain any market share?
Yes, through brand loyalty, physician preferences, and rebates, the originator can retain a portion of the market, especially for high-volume patients.
4. How does biosimilar price competition differ globally?
In Europe, biosimilar penetration began earlier, leading to larger price reductions (~30%), whereas in the US, legal battles and payer strategies slow adoption.
5. What factors could influence the actual price trajectory?
Legal outcomes, regulatory decisions, reimbursement strategies, and biosimilar manufacturing costs will shape future pricing.
Sources:
- EvaluatePharma. "Global Humira sales."
- FDA. "Biosimilar approvals and market entry."
- IQVIA. "US biologic market forecasts."
- GoodRx. "Humira prices and discounts."
- Impact of patent expiry on biologic markets.
